NewsTradingSentimentCalendarCommunityBriefing
Sign in
Stocks

NeoGenomics Q2 Revenue Tops Estimates While RadNet Leads Sector Growth

By Stocks Desk · 2026-09-12 · 1 min read
A modern laboratory bench featuring glass test tubes and microscopes.
Illustration: Tradingbird

NeoGenomics exceeded revenue expectations by 2.2% in Q2, joining a group of diagnostics firms that collectively beat consensus by 2.8%.

NeoGenomics reported second-quarter revenue of $201.7 million, an 11.2% year-over-year increase that surpassed analyst consensus by 2.2%. The company also posted an earnings-per-share beat against full-year guidance, marking a solid performance within the testing and diagnostics sector.

According to data from GN stocks/nasdaq, the five tracked companies in this industry segment delivered a collective revenue beat of 2.8% against estimates. Following the earnings releases, the group’s average share price has risen 9.4%, reflecting investor confidence in the sector’s current trajectory.

NeoGenomics Drives Strong Operational Results

Operating through CAP-accredited and CLIA-certified laboratories in the US and UK, NeoGenomics focuses on specialized cancer diagnostics, including genetic analysis and molecular testing. CEO Tony Zook attributed the results to consistent operating and financial performance, highlighting the stability of the company’s service delivery.

Since reporting its earnings, NeoGenomics shares have climbed 30.9% to $17.54. This significant gain positions the company as a top performer in the group, driven by its ability to meet and exceed both quarterly and annual financial targets.

RadNet Posts Highest Revenue Growth

RadNet, which operates over 350 imaging facilities across seven states, recorded the highest revenue growth in the peer group. Its Q2 revenue reached $622.7 million, a 25% year-over-year increase that exceeded analyst expectations by 2.3%.

The company also beat EPS estimates for the quarter. Despite the strong fundamental performance, RadNet’s stock has seen only a modest 1% increase since the report, currently trading at $73.15.

Labcorp Lags Peers In Growth

Labcorp reported Q2 revenue of $3.73 billion, up 5.8% year-over-year, which aligned with analyst expectations. While the company beat its full-year EPS guidance, it posted the slowest revenue growth and weakest guidance update among the tracked diagnostics firms.

The market reaction to Labcorp’s results has been neutral, with the stock remaining flat since the announcement. Shares currently trade at $308.72, reflecting a lack of immediate momentum compared to the sharper gains seen in NeoGenomics and RadNet.

Based on reporting by TradingView, compiled by the Tradingbird desk.

Read next

More in Stocks
A glass test tube with clear liquid on a white lab bench
Stocks · Healthcare

Qiagen Q2 Earnings Beat Estimates Amid UBS Rating Upgrade

Qiagen reported second-quarter revenue of $535 million and a 19.3% profit margin, slightly exceeding analyst expectations. UBS lifted its stance to Hold, aligning with a broader consensus that views the diagnostics firm as stable but lacking significant near-term upside.

2026-09-12Illustration: Tradingbird
A glass vial containing a clear liquid standing on a white laboratory bench
Stocks · Healthcare

Immuneering Market Cap Drops 36 Million as Insiders Face Losses

Immuneering's market value slid by US$36 million, erasing the value of recent insider purchases despite a lack of selling activity.

2026-09-12Illustration: Tradingbird
A glass vial containing a clear liquid standing on a white laboratory bench
Stocks · Healthcare

Lexeo Therapeutics Maintains 2.4 Year Cash Runway Despite Reduced Burn

Lexeo Therapeutics holds $212m in cash with a 2.4-year runway, having reduced annual burn by 6.9% to $89m.

2026-09-12Illustration: Tradingbird

More from the Stocks desk

All desk stories
  • A pile of grey, granular mineral powder next to a clear glass beaker containing a pale yellow liquid
    Illustration: Tradingbird

    CREG Dominates Heavy Rare Earth Separation Amidst Import Surge

    China Rare Earth Group controls the strategic midstream chokepoint, processing 98% of global heavy rare earth oxides while integrating Myanmar and Malaysian feedstocks.

    2026-09-12
  • A single gold coin resting on a polished wooden desk surface
    Illustration: Tradingbird

    Amalgamated Financial Chief Banking Officer Sells 87% of Holdings

    Sam Brown, Senior EVP and Chief Banking Officer of Amalgamated Financial Corp., has executed a significant divestment, selling shares worth US$1.5 million. This transaction represents a substantial reduction in personal equity exposure for a key executive.

    2026-09-12
  • A close-up of a green printed circuit board with intricate copper traces and a central black integrated circuit chip
    Illustration: Tradingbird

    Astera Labs Posts 2.35% Gain Amid High Valuation Premium

    Astera Labs shares rose 2.35% to $291.22, outperforming the S&P 500 despite an 11.85% monthly decline. The company faces a steep valuation hurdle with a forward P/E of 71.6, significantly above the industry average, as investors await strong earnings growth estimates.

    2026-09-12